UBS Group
BCTX

UBS Group’s Briacell Therapeutics BCTX Stock Holding History

UBS Group’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.4K Buy
11,541
+10,903
+1,709% +$50.8K ﹤0.01% 7388
2025
Q4 		$4.54K Buy
638
+574
+897% +$6.06K ﹤0.01% 8817
2025
Q3 		$704 Sell
64
-1,460
-96% -$15.3K ﹤0.01% 9561
2025
Q2 		$44.8K Sell
1,524
-383
-20% -$14K ﹤0.01% 7861
2025
Q1 		$69.6K Buy
1,907
+1,643
+622% +$78.4K ﹤0.01% 7333
2024
Q4 		$22.4K Buy
264
+259
+5,180% +$31K ﹤0.01% 7800
2024
Q3 		$985 Buy
+5
New +$562 ﹤0.01% 8758
2024
Q1 		– Hold
0
– -$88 – 9309
2023
Q4 		– Hold
0
– – – 8940
2023
Q2 		– Sell
-1
Closed -$1.26K – 8921
2023
Q1 		$1.26K Buy
+1
New +$1.04K ﹤0.01% 8774
2022
Q3 		– Sell
-11
Closed -$10K – 10328
2022
Q2 		$10K Buy
11
+9
+450% +$8.89K ﹤0.01% 7943
2022
Q1 		$3K Sell
2
-7
-78% -$8.28K ﹤0.01% 9423
2021
Q4 		$12K Sell
9
-12
-57% -$15.7K ﹤0.01% 8544
2021
Q3 		$25K Sell
21
-68
-76% -$62.5K ﹤0.01% 6909
2021
Q2 		$71K Buy
89
+85
+2,125% +$53K ﹤0.01% 6127
2021
Q1 		$2K Buy
+4
New +$2.17K ﹤0.01% 8595

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group's BCTX Position: Q1 2026 in Review

UBS Group increased its Briacell Therapeutics (BCTX) stake by 1,709% in Q1 2026, buying an estimated $50.8K and bringing the position to 11,541 shares worth $48.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7388.

UBS Group first reported a position in BCTX in Q1 2021 and has held it in 14 quarters since. The position peaked at $71K in Q2 2021. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • UBS Group held 11,541 shares of Briacell Therapeutics worth $48.4K as of Q1 2026.
  • UBS Group bought 10,903 Briacell Therapeutics shares in Q1 2026, an estimated $50.8K.
  • Briacell Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7388 holding.
  • UBS Group first reported a position in Briacell Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • UBS Group's Briacell Therapeutics position peaked at $71K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.